ReshmaRangwalaMD

Hospital Medicine/Hospitalist, Hematology/Oncology

Physician

Are you Dr. Rangwala?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 52 invites waiting!
Read the latest clinical news, personalized to your specialty.

Office
1 Barnes Jewish Hospital Plz
Saint Louis, MO 63110
Phone+1 314-362-1700

Fax+1 314-362-9878

Dr. Reshma Rangwala, MD is an internist in Saint Louis, Missouri. She is currently licensed to practice medicine in Pennsylvania.

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
University of Cincinnati College of MedicineClass of 2006

PubMed

63 citations
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
David S. Hong, Nicole Concin, Ignace Vergote, Johann S. de Bono, Brian M. Slomovitz
Clinical Cancer Research. 2020-03-15
125 citations
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
Johann S. de Bono, Nicole Concin, David S. Hong, Fiona C Thistlethwaite, Jean-Pascal Machiels
The Lancet. Oncology. 2019-03-01
285 citations
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
Reshma Rangwala, Robert D. Leone, Yunyoung C. Chang, Leslie A. Fecher, Lynn M. Schuchter
Autophagy. 2014-05-20

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisOctober 31st, 2024
$Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS$
Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDSMay 3rd, 2023
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 ObjectivesJanuary 9th, 2023
Join now to see all